Alnylam Pharmaceuticals Inc (ALNY)vsImmutep Ltd ADR (IMMP)
ALNY
Alnylam Pharmaceuticals Inc
$303.05
-0.19%
HEALTHCARE · Cap: $37.76B
IMMP
Immutep Ltd ADR
$0.38
-3.09%
HEALTHCARE · Cap: $55.50M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 54009% more annual revenue ($4.29B vs $7.92M). ALNY leads profitability with a 12.6% profit margin vs 0.0%. ALNY earns a higher WallStSmart Score of 65/100 (B-).
ALNY
Strong Buy65
out of 100
Grade: B-
IMMP
Hold35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.4%
Fair Value
$2372.19
Current Price
$303.05
$2069.14 discount
Intrinsic value data unavailable for IMMP.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 96.4% year-over-year
Strong operational efficiency at 23.0%
Reasonable price relative to book value
Revenue surging 91.5% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 37.6x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Revenue growth of 96.4% demonstrates continued momentum. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : IMMP
The strongest argument for IMMP centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 91.5% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, Debt/Equity, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.
Bear Case : IMMP
The primary concerns for IMMP are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ALNY profiles as a growth stock while IMMP is a hypergrowth play — different risk/reward profiles.
IMMP carries more volatility with a beta of 2.24 — expect wider price swings.
ALNY is growing revenue faster at 96.4% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ALNY scores higher overall (65/100 vs 35/100) and 96.4% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Immutep Ltd ADR
HEALTHCARE · BIOTECHNOLOGY · USA
Immutep Limited, a biotechnology company, is dedicated to the research and development of pharmaceutical candidates. The company is headquartered in Sydney, Australia.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?